Pfizer Inc.
CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
Last updated:
Abstract:
The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
Status:
Application
Type:
Utility
Filling date:
15 Apr 2019
Issue date:
8 Aug 2019